Vikram Narayan discusses detalimogene voraplasmid (EG-70), a non-viral therapy for bladder cancer that uses a proprietary delivery mechanism to introduce DNA plasmid into the bladder. EG-70 employs a ...

(UroToday.com) The 2025 APCCC Diagnostics annual meeting featured a session on how to stage and estimate risk for prostate cancer and a presentation by Dr. Daniel Spratt discussing the added value of ...

(UroToday.com) Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics 2025 held in Lugano, Switzerland was host to a session addressing the contemporary management of metastatic prostate ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Annual Symposium held in San Francisco, CA between February 13–15, 2025 was host to a renal cell cancer rapid ...

(UroToday.com) The 2025 SESAUA annual meeting featured a bladder cancer session and a presentation by Dr. Meredith Bernhard discussing the oncologic efficacy of reduced versus standard-dose BCG for ...

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...

The 2024 ESMO Annual Congress was host to the session Updates in the management of advanced renal cell carcinoma. Dr. Teresa Alonso Gordoa discussed systemic treatment options for the management of ...

Saikali S, Khosravi P, Gamal A, et al. MP07-02 Detection of Prostate Cancer Extracapsular Extension with MRI Using Deep Learning Methods. J Urol. 2024 May;211 (5S):e105.

The encore results from the Phase 3 BOND-003 Cohort C study demonstrate that intravesical cretostimogene grenadenorepvec provides a high complete response rate (74.5%) in patients with ...

As we celebrate Women's History Month, we recognize the many incredible women who have contributed to educating the global urology and oncology communities through UroToday-GU Oncology Today®. We ...